| Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 | 4385 | 2018 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1018 | 2019 |
| Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer HMD Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal ... J Clin Oncol 36 (https://www.ncbi.nlm.nih.gov/pubmed/3012), 2872-2878, 2018 | 868 | 2018 |
| Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ... JAMA oncology 4 (3), 351-357, 2018 | 704 | 2018 |
| Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA oncology 4 (11), 1543-1552, 2018 | 685 | 2018 |
| Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria M Tazdait, L Mezquita, J Lahmar, R Ferrara, F Bidault, S Ammari, ... European Journal of Cancer 88, 38-47, 2018 | 303 | 2018 |
| Outcome of patients with non–small cell lung cancer and brain metastases treated with checkpoint inhibitors LEL Hendriks, C Henon, E Auclin, L Mezquita, R Ferrara, ... Journal of Thoracic Oncology 14 (7), 1244-1254, 2019 | 210 | 2019 |
| Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations J Remon, F Passiglia, MJ Ahn, F Barlesi, PM Forde, EB Garon, ... Journal of Thoracic Oncology 15 (6), 914-947, 2020 | 144 | 2020 |
| Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer G Recondo, L Mezquita, F Facchinetti, D Planchard, A Gazzah, L Bigot, ... Clinical Cancer Research 26 (1), 242-255, 2020 | 142 | 2020 |
| Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter? R Ferrara, L Mezquita, E Auclin, N Chaput, B Besse Cancer treatment reviews 60, 60-68, 2017 | 140 | 2017 |
| Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer E Pailler, V Faugeroux, M Oulhen, L Mezquita, M Laporte, A Honoré, ... Clinical Cancer Research 25 (22), 6671-6682, 2019 | 115 | 2019 |
| Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors RD Seban, L Mezquita, A Berenbaum, L Dercle, A Botticella, ... European journal of nuclear medicine and molecular imaging 47, 1147-1157, 2020 | 113 | 2020 |
| Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. F Skoulidis, KC Arbour, MD Hellmann, PD Patil, ME Marmarelis, ... Journal of Clinical Oncology 37 (15_suppl), 102-102, 2019 | 104 | 2019 |
| CD103+ CD8+ TRM cells accumulate in tumors of anti-PD-1-responder lung cancer patients and are tumor-reactive lymphocytes enriched with Tc17 S Corgnac, I Malenica, L Mezquita, E Auclin, E Voilin, J Kacher, H Halse, ... Cell Reports Medicine 1 (7), 2020 | 92 | 2020 |
| Circulating T-cell immunosenescence in patients with advanced non–small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy R Ferrara, M Naigeon, E Auclin, B Duchemann, L Cassard, JM Jouniaux, ... Clinical Cancer Research 27 (2), 492-503, 2021 | 90 | 2021 |
| 1215O-SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial B Besse, J Adam, N Cozic, N Chaput-Gras, D Planchard, L Mezquita, ... Annals of Oncology 31, S794-S795, 2020 | 88 | 2020 |
| Clarification of definitions of Hyperprogressive disease during immunotherapy for non–small cell lung cancer B Kas, H Talbot, R Ferrara, C Richard, JP Lamarque, S Pitre-Champagnat, ... JAMA oncology 6 (7), 1039-1046, 2020 | 82 | 2020 |
| Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients J Remon, L Mezquita, J Corral, N Vilariño, N Reguart Journal of Thoracic Disease 10 (Suppl 13), S1516, 2018 | 76 | 2018 |
| Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer F Facchinetti, L Lacroix, L Mezquita, JY Scoazec, Y Loriot, L Tselikas, ... European Journal of Cancer 132, 211-223, 2020 | 67 | 2020 |
| Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression M Aldea, L Hendriks, L Mezquita, C Jovelet, D Planchard, E Auclin, ... Journal of Thoracic Oncology 15 (3), 383-391, 2020 | 64 | 2020 |
